VBI Vaccines Inc (VBIV) has released an update.
VBI Vaccines Inc. has enhanced its partnership with the Canadian government, receiving an additional CAD$28 million to further develop its innovative mRNA-launched eVLP vaccine technology, which shows promise in provoking strong immune responses. The collaboration aims to improve vaccine manufacturing processes and contribute to epidemic and pandemic preparedness with a focus on a pan-coronavirus vaccine candidate. VBI’s technology, which is currently being evaluated by potential partners, has the potential to significantly advance particulate vaccine development.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.
